IDYA
Ideaya Biosciences Inc

1,287
Mkt Cap
$3.02B
Volume
570,918.00
52W High
$39.28
52W Low
$13.45
PE Ratio
-18.72
IDYA Fundamentals
Price
$34.74
Prev Close
$34.47
Open
$34.54
50D MA
$34.82
Beta
1.17
Avg. Volume
927,174.95
EPS (Annual)
-$3.36
P/B
2.79
Rev/Employee
$53,435.11
Loading...
Loading...
News
all
press releases
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seventeen analysts that are covering the company, Marketbeat Ratings...
MarketBeat·17h ago
News Placeholder
More News
News Placeholder
IDEAYA Biosciences, Inc. $IDYA Stake Lifted by SG Americas Securities LLC
SG Americas Securities LLC boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 169.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·11d ago
News Placeholder
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·15d ago
News Placeholder
IDYA March 20th Options Begin Trading
Investors in IDEAYA Biosciences Inc (Symbol: IDYA) saw new options begin trading today, for the March 20th expiration. One of the key inputs that goes into the price an option buyer is willing to...
Nasdaq News: Markets·21d ago
News Placeholder
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference PR...
PR Newswire·23d ago
News Placeholder
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the firm, Marketbeat.com reports. One...
MarketBeat·26d ago
News Placeholder
IDEAYA Biosciences Sees Unusually Large Options Volume (NASDAQ:IDYA)
IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of unusually large options trading activity on Tuesday. Investors bought 9,011 call options on the stock. This is an increase...
MarketBeat·28d ago
News Placeholder
Squarepoint Ops LLC Sells 51,937 Shares of IDEAYA Biosciences, Inc. $IDYA
Squarepoint Ops LLC trimmed its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 58.1% in the second quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·1mo ago
News Placeholder
Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA
Redmile Group LLC reduced its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 19.1% during the 2nd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·2mo ago
News Placeholder
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal...
PR Newswire·2mo ago
<
1
2
...
>

Latest IDYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.